716 McKesson Corporation $MCK Shares Acquired by Brighton Jones LLC

Brighton Jones LLC lifted its stake in shares of McKesson Corporation (NYSE:MCK) by 22.5% during the 3rd quarter, Holdings Channel reports. The fund owned 3,902 shares of the company’s stock after buying an additional 716 shares during the quarter. Brighton Jones LLC’s holdings in McKesson were worth $3,332,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rosenberg Matthew Hamilton increased its position in McKesson by 2.8% during the third quarter. Rosenberg Matthew Hamilton now owns 406 shares of the company’s stock worth $347,000 after purchasing an additional 11 shares during the last quarter. Avail Investment Partners LLC grew its stake in shares of McKesson by 1.7% in the 3rd quarter. Avail Investment Partners LLC now owns 662 shares of the company’s stock valued at $566,000 after buying an additional 11 shares during the period. Commonwealth Financial Services LLC increased its holdings in shares of McKesson by 3.8% during the 3rd quarter. Commonwealth Financial Services LLC now owns 304 shares of the company’s stock worth $260,000 after buying an additional 11 shares during the last quarter. WealthPLAN Partners LLC increased its holdings in shares of McKesson by 0.4% during the 3rd quarter. WealthPLAN Partners LLC now owns 3,190 shares of the company’s stock worth $2,724,000 after buying an additional 12 shares during the last quarter. Finally, Arista Wealth Management LLC raised its position in shares of McKesson by 1.0% during the 2nd quarter. Arista Wealth Management LLC now owns 1,446 shares of the company’s stock valued at $1,093,000 after buying an additional 14 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

McKesson Stock Down 0.0%

Shares of NYSE MCK opened at $1,060.79 on Monday. The firm has a market cap of $122.48 billion, a price-to-earnings ratio of 27.28, a PEG ratio of 1.97 and a beta of 0.27. McKesson Corporation has a 52-week low of $723.68 and a 52-week high of $1,121.50. The business’s 50 day moving average is $938.13 and its two-hundred day moving average is $868.12.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, topping the consensus estimate of $10.72 by $0.96. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The business had revenue of $110.96 billion during the quarter, compared to analyst estimates of $109.90 billion. During the same period last year, the business posted $9.86 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Analysts anticipate that McKesson Corporation will post 46.21 EPS for the current fiscal year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is presently 9.67%.

Analyst Ratings Changes

MCK has been the topic of a number of recent analyst reports. UBS Group upped their price objective on McKesson from $1,200.00 to $1,250.00 and gave the company a “buy” rating in a report on Thursday. Barclays raised their target price on McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Robert W. Baird set a $1,015.00 target price on McKesson in a research report on Thursday, August 6th. Wells Fargo & Company upped their price target on McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. Finally, TD Cowen increased their price target on McKesson from $1,006.00 to $1,200.00 and gave the stock a “buy” rating in a report on Thursday. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,026.18.

Insider Activity at McKesson

In related news, CAO B Jr sold 111 shares of McKesson stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the transaction, the chief accounting officer owned 521 shares in the company, valued at approximately $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 800 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $995.80, for a total transaction of $796,640.00. Following the sale, the executive vice president directly owned 5,423 shares in the company, valued at approximately $5,400,223.40. The trade was a 12.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 2,161 shares of company stock valued at $2,242,515. Insiders own 0.06% of the company’s stock.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.